leadf
logo-loader
viewEvgen Pharma PLC

Evgen Pharma recruits over 100 patients for COVID-19 treatment study

The firm said it is an important milestone bringing it a step closer to receiving the initial data from the trial

Evgen Pharma PLC - Evgen Pharma recruits over 100 patients for COVID-19 treatment study

Evgen Pharma PLC (LON:EVG) said 102 patients had been recruited and randomised to the STAR trial for its COVID-19 treatment as of Tuesday.

This Phase II/III trial is a randomised, placebo-controlled trial, sponsored by the University of Dundee and funded by the UK charity LifeArc, the drug developer said.

READ: Evgen Pharma raises funds to accelerate clinical and pre-clinical work

It is investigating whether the company's lead asset, SFX-01, can reduce the severity, or prevent the onset of, acute respiratory distress syndrome in patients with suspected COVID-19.

Patients may be included in the study if they are infected with SARS-CoV-2 or other respiratory infections causing community-acquired pneumonia, the AIM-listed firm added.

The trial design includes an assessment of safety and futility by a Data Safety and Monitoring Board (DSMB) who will review unblinded data on the first 100 patients treated.

In addition to the DSMB safety and futility assessment, Dundee University has decided to review the top-level unblinded data in a preliminary assessment of possible efficacy.

This may lead to adjustments to the design of the trial for remaining patients, including in patient numbers, and possibly early termination for either safety, futility or alternatively, strong efficacy, Evgen said.

It is expected that this initial data will be available during the second quarter of calendar 2021.

The university has also requested the DSMB review data from the first 60 patients solely for safety and this process will be starting shortly, with an outcome expected to be available early in the second quarter.

The pharma company said that completion of recruitment to the STAR trial is anticipated at the end of the year, assuming there are no substantial changes in the total patients to be recruited.

“Randomising over 100 patients is an important milestone in this trial and takes us a step closer to receiving the initial data from the study,” said chief executive Dr Huw Jones in a release.

Quick facts: Evgen Pharma PLC

Price: 8 GBX

AIM:EVG
Market: AIM
Market Cap: £21.99 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Evgen Pharma PLC named herein, including the promotion by the Company of Evgen Pharma PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Market Report: FTSE falls and UK inflation up to 0.7% on back of rising food...

FTSE 100 opened in the red after the latest inflation data came in higher than forecasts. London’s leading index lost 14 points to 6,734 in early trading.   UK prices rose 0.7% in the year to January and are expected to jump further as demand increases over the next months. Food and more...

2 weeks, 2 days ago

2 min read